This inventor holds 2 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignee: Shanghaitech University. Active years: 2022-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022-2026
Title: Francesco Zonta: Innovator in Antibody Research
Introduction
Francesco Zonta is a prominent inventor based in Shanghai, China. He is known for his significant contributions to the field of biotechnology, particularly in the development of antibodies. His innovative work has the potential to impact the treatment of various diseases associated with Connexin mutations.
Latest Patents
Francesco Zonta holds a patent for a fully human antibody specifically inhibiting Connexin 26. This invention is characterized as a recombinant immunoglobulin with the structure of scFv-Fc. The antibody utilizes the first 41-56 amino acid sequence of the extracellular region of Connexin 26 as an antigen, with the sequence being KEVWGDEQADFVCNTL. Through biochemical analysis and immunofluorescence identification, it has been confirmed that this antibody can specifically recognize Connexin 26 and inhibit its hemichannel activity. Animal experiments have demonstrated that the antibody significantly inhibits the hemichannel activity of mouse cochlear tissue sections. This breakthrough suggests that the antibody could be utilized in the treatment of Connexin mutation-associated diseases.
Career Highlights
Francesco Zonta is affiliated with ShanghaiTech University, where he conducts his research and development activities. His work has garnered attention in the scientific community, particularly for its innovative approach to antibody design and application.
Collaborations
Francesco has collaborated with notable colleagues, including Zhihu Qu and Guang Yang. Their combined expertise contributes to the advancement of research in the field of biotechnology.
Conclusion
Francesco Zonta's work in developing a fully human antibody against Connexin 26 represents a significant advancement in medical research. His contributions have the potential to lead to new treatments for diseases related to Connexin mutations.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile